SC263 / Sana Biotech - LARVOL DELTA

Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization (GlobeNewswire) - "Select Program Review: (i) SC263 (HIP-modified, CD22-targeted allogeneic CAR T) - Sana expects to file an IND in 2023....This therapy has the potential to treat patients with B cell malignancies who have failed previous CAR T therapies; (ii) SG295 (in vivo CAR T with CD8-targeted fusogen delivery of a CD19-targeted CAR) - Sana remains on track to file an IND in 2023....The company expects to study this therapy in patients with B cell malignancies; (iii) SC255 (HIP-modified, BCMA-targeted allogeneic CAR T) - Sana expects to file an IND in 2024 to treat multiple myeloma."

IND • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology